NCT02262611已完成不适用
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 266
- 主要终点
- Change in systolic blood pressure
研究概览
简要总结
Study to obtain long-term data on effects, safety and tolerability in routine medical practice and to investigate the potential of telmisartan to prevent secondary organ damage
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients of both gender aged >=18 admitted to a hospital due to insufficiently controlled essential hypertension.
- •No additional selection criteria have to be considered. Treatment was at the discretion of the physician following the summary of product information for Micardis® and MicardisPlus®
排除标准
- •not applicable
研究组 & 干预措施
Hypertension patients - Diabetology
干预措施: MicardisPlus® (Drug)
Hypertension patients - Diabetology
干预措施: Micardis® (Drug)
Hypertension patients - Pneumology
干预措施: Micardis® (Drug)
Hypertension patients - Pneumology
干预措施: MicardisPlus® (Drug)
Hypertension patients - Cardiology
干预措施: Micardis® (Drug)
Hypertension patients - Cardiology
干预措施: MicardisPlus® (Drug)
Hypertension patients - Nephrology
干预措施: Micardis® (Drug)
Hypertension patients - Nephrology
干预措施: MicardisPlus® (Drug)
结局指标
主要结局
Change in systolic blood pressure
时间窗: up to 1 year
Number of patients with adverse events
时间窗: up to 1 year
Number of patients with abnormal changes in laboratory parameters
时间窗: up to 1 year
Change in diastolic blood pressure
时间窗: up to 1 year
Number of patients with clinically significant changes in vital signs
时间窗: up to 1 year
次要结局
- Global assessment of efficacy by investigator on a 4-point scale(2 weeks, after 1 year)
- Global assessment of tolerability by investigator on a 4-point scale(2 weeks, after 1 year)
研究者
相似试验
已完成
不适用
Lyrica (Pregabalin) Korean Post Marketing Surveillance StudyNeuropathic PainPost-market SurveillanceEpilepsyFibromyalgiaNCT01220180Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4,175
招募中
不适用
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac ArrhythmiasNCT04750798Biosense Webster, Inc.8,000
暂停
不适用
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeChronic Lymphocytic Leukemia (CLL)NCT03659669AbbVie272
已完成
不适用
PMCF to Assess Real-life Usage Effectiveness, Safety and Patient Satisfaction of a Range of Hypertonic Seawater-based Decongestant Nasal SpraysURTIAllergic RhinitisNCT06104332Laboratoire de la Mer534
终止
不适用
Observational Study Conducted on Patients Receiving the ESOP 2 Stem to Confirm Security and Performance of the DeviceHip DiseaseHip FracturesNCT04193163FH ORTHO10